



BIONOVELUS

GREEN SOLUTIONS FOR THE 21ST CENTURY

BIONOVELUS, INC.

A Nevada Corporation

2018 Q3 Report

For Quarter Ending September 30, 2018

This Report contains forward-looking statements which reflect the Company's current views with respect to future events and financial performance. All statements other than statements of historical facts contained in this report, including statements regarding our future financial position, business strategy, and plans and objectives of management for future operations, are forward-looking statements. The words "believe," "expect," "anticipate," "intend," "estimate," "forecast," "project," and similar expressions identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations; any statements concerning proposed new products, services, developments, or the status of competitors; any statements regarding future economic conditions or performance; any statements of belief; any statements regarding the validity of our intellectual property; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements are subject to risks and uncertainties.

BioNovelus, Green Solutions for the 21st Century

BioNovelus, Inc. (US OTC Pink: ONOV) is a bioscience company whose vision is to answer critical problems to crop protection, food and water security, and health challenges by replacing harmful chemicals with eco-friendly and profitable technologies in respect to our planet. Its mission is to offer disruptive green technologies that are innovative, cost-effective solutions for BioNovelus' customers, and partners, and benefit the shareholders and the planet at large.

There is an urgent need to keep ahead of both current and future pathogens, viruses and bacteria as well their resistant superbugs. Current products, many of which are toxic, while effective against many of these dangerous microbes, are corrosive, unstable, dangerous for transportation, cannot prevent re-infection, and even contributes to the creation of more superbugs.

1) The exact name of the issuer and its predecessor (if any)

BioNovelus, Inc.

Firstin Wireless Technology, Inc. (until May 15, 2015)

Formerly Passionate Pet, Inc. (until January 31, 2013)

2) The address of the issuer's principal executive offices

275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel.: 1(888)924-6668 ext.0
Website: <http://bionovelus.com>

IR Contact

Jean Ekobo
BioNovelus Inc.
275 N. Gateway Drive
Suite 130
Phoenix, AZ 85034
Tel.: 1(888)924-6668 ext. 0
Email: investor.relations@bionovelus.com

3) Security Information

Trading Symbol: ONOV

Exact title and class of securities outstanding:

Common CUSIP: 09073X100

Par or Stated Value: \$0.001

Total shares authorized: 500,000,000 as of: September 30, 2018

Total shares outstanding: 118,632,959 as of: September 30, 2018

Exact title and class of securities outstanding: Preferred

CUSIP: None

Par or Stated Value: \$0.001

Total shares authorized: 10,000,000 as of: September 30, 2018

Total shares outstanding: 10,000,000 as of: September 30, 2018

Transfer agent Natco Nevada Agency and Transfer Company

50 West Liberty Street, suite 880

Reno, NV, 89501

Phone: 775-322-0626

Fax: 775-322-5623

Email: tiffany@natco.org

Natco is registered with the Securities and Exchange Commission as a transfer agent pursuant to Section 17A(c) of the Exchange Act.

No restrictions on the transfer of security other than the standard SEC restrictions.

No trading suspension orders issued by the SEC in the past 12 months.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On January 22, 2013 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Passionate Pet, Inc. to Firstin Wireless Technology, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 250 basis which was effected on January 31, 2013. On March 30, 2015 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Firstin Wireless Technology, Inc. to BioNovelus, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 750 basis.

4) Issuance History

During the year 2015, the Company issued common shares as described below: 70,000,000 shares of common stock pursuant to the acquisition agreement with BioNovelus, Inc.

During the third Quarter of 2018, the Company issued common shares as described in the table below.

- a) Compensation for services: Information regarding equity compensation plans has been approved by the board of directors and majority shareholders.
- b) Private Offerings: These offerings were conducted under Rule 4(2) of Securities Act of 1933.

All shares issued contained a restricted legend stating that the shares have not been registered under the Securities Act and this legend further set forth the restrictions on transferability and sale of the shares under the Securities Act.

Date	Name	Description	Amount	Cost of Services	Shares	Price per Share
		Stock ledger balance at 1/1/2018	255899.74	633346.31	112,139,077	
06/21/2018	Nathalie Ekobo	Restricted stock-Payroll	60,000.00	60,000.00	1,333,333	0.045
06/21/2018	Jean Ekobo	Restricted stock-Payroll	90,000.00	90,000.00	2,000,000	0.045
06/28/2018	Louise Benz	Restricted stock purchase	11,800.00	0.00	429,010	0.0275
07/19/2018	Samuel E Ashut	Restricted stock purchase	5,000.00	0.00	200,000	0.042
08/20/2018	Louise Benz	Restricted stock purchase	6,000.00	0.00	238,095	0.03
07/19/2018	Marlyse Fournier	Restricted stock purchase - Services	70,000.00	70,000.00	1,666,667	0.0275

5) Financial Statements

The Issuer is providing the following financial statements for the quarter ending September 30, 2018 and financial notes, both of which have been filed with OTC Markets on November 14, 2018. These unaudited financial statements and financial notes are incorporated by reference herein.

- A. Balance sheet
- B. Statement of income
- C. Statement of cash flows
- D. Financial notes.

6) Describe the Issuer's Business, Products and Services

The Company originally operated a retail pet and supply store in Irvine, California which ran its operations and also sold retail premium pet food, supplies and service to the general public, through a wholly owned subsidiary. The Company decided to dispose of its operating business primarily because it had incurred significant operating losses in each of the last two years as the operations could not generate enough revenues to satisfy the significant rent and occupancy costs. On July 31, 2012, the former CEO, John Dunn entered into an agreement with the Company to sell 100% of his interest in the Company and assume the net assets and liabilities of the wholly owned subsidiary. As a result, the subsidiary together with its assets and liabilities were wholly owned by Mr. Dunn.

On January 23, 2013, the Company entered into a Share Exchange Agreement with the Firstin Wireless Technology, Inc., a corporation formed under the laws of Canada (Firstin Canada), and the shareholders of Firstin Canada. Under the terms of this agreement, Firstin Canada became the wholly owned subsidiary of the Company. On April 22, 2015, the Company entered into an Amalgamation Agreement with BioNovelus, Inc., an Arizona corporation.

The following business description and discussion regarding products relates to the operations of BioNovelus, Inc.

A. Description of the issuer's business operations

BioNovelus' first product, CR-10®, a fungicide, is a fast-acting disinfectant. This biodegradable product is non-toxic, resistant to high temperatures, flocculent, non-corrosive, and hold properties that positively affect water.

CR-10® available markets for commercialization are Hard Surface Disinfectant; Agricultural Treatment.

Our go-to-market strategy is to first build relationships with large farmers, cooperatives, exporters, and food packers, and show them that we can help increase productivity, and food and workers safety, while reducing labor costs.

We partner with them to test our products and show concrete results and potential ROI. We gain adoption through farmer's support and build reputation to obtain trade associations validation leading to full scaling opportunity.

At the same time, we register the product in the countries with the appropriate authorities.

Once the brand is established, we plan to sign distribution agreements with sales goals, territories, applications. We also plan to license the product on specific applications to companies that are already established in the markets we target.

We will support the distributors with marketing material, participation to trade shows and events, and sales training.

For its operations in Central America, BioNovelus Inc. has a subsidiary in Costa Rica, BioNovelus-Costa Rica SA, and an importer in Guatemala.

CR-10® has been registered as a disinfectant by the Ministry of Health in Guatemala in 2017. We are in process of registering CR-10® in Costa Rica. The process of registration as a biofungicide through the Ministry of Agriculture is expected to follow.

- B. The Company (originally “Passionate Pet Inc.”) was incorporated in the State of Nevada in September 2010.**
- C. The Issuer’s primary SIC Code is 2879.**
- D. The Issuer’s fiscal year end date is December 31.**
- E. The Company’s principal products or services, and their markets:**

Crop Protection

Between 26 to 40 percent of the world’s annual crop production is lost to weeds, pests and diseases. These losses could rise without the use of crop protection practices. Moreover, additional losses from spoilage can be delayed once produce enters the food distribution system.

At BioNovelus, we work directly with farmers, listening to their concerns and addressing their needs. One fear that is expressed is the escalated need to use evermore toxic chemicals as bacteria and fungi become resistant to the chemical agents currently being used. Additionally, vegetable and fruit producers also talk about depletion of the soil’s nutrients and yield reduction.

BioNovelus offers farmers a healthier alternative to combat harmful pathogens, resulting in higher crop yields while restoring organic nutrients to the soil.

Field trials on killing pathogens such as Botrytis, Tizon, Alternaira, and Phytoctora (Tomato, Pepper, Zucchini, etc.) have been completed in 2017, and show positive results with an increase of yield.

Crop Protection for Coffee:

Since 2016, BioNovelus' primary target market is the worldwide coffee industry, which is valued at over \$100B a year annually according to Business Inside. This industry has been plagued by "Coffee Leaf Rust" or "Roya" (Hemileia vastatrix) a devastating fungus that attacks the Arabica plant. Over \$3B and 700K jobs have been lost just throughout Central America since 2012 to this Coffee Rust epidemic (Source: ICafé). Because of this fungus, coffee production in Central America and Mexico dropped by 40 - 60% in 2015 and 2016.

Traditional coffee growers have access to chemical products, even though these toxic products are not that effective on coffee rust that becomes a resistant fungus, but when it comes to organic coffee growers, (that are becoming a larger market due to the consumer demand for organic coffee,) these organic farmers do not have any effective organic treatment for coffee rust. We chose to focus on this sub-market first, because CR-10® is well positioned to answer a crucial and unmet need.

There are approximately 80,000 hectares of organic coffee trees - just in Guatemala. We believe that by establishing a successful track record with the organic coffee growers of Guatemala, we will be able to generate positive reviews and word-of-mouth to facilitate the penetration into the traditional coffee growers. Once we have proved it in Guatemala, the other countries of Central America, Mexico, and Colombia, may follow.

Post-Harvest

One point three billion tons of food is wasted or lost each year. This represents 340 pounds of food lost or wasted for every person on the planet, which otherwise could have fed 1.6 billion more people each year. The retail value of lost and wasted food costs the global economy more than \$12.5 trillion.

Each day, 759 million people go hungry. One billion, three hundred million tons of food is wasted or lost each year. This represents 340 pounds of food lost or wasted for every person on the planet. This could feed 1.6 billion more people each year. The CR-10® performance of improving food security, Post-Harvest an obvious and huge potential market to serve.

CR-10® can improve food security by increasing shelf life (results vary depending on the type of crop), making post-harvest an obvious, and huge market.

Our potential customers are food packers, and vegetable/fruit exporters. By treating their produce with CR-10®, they will increase the food security by killing all the food-borne disease pathogens, improve the quality of their produce, and extend shelf life.

Additionally, food distributors and grocery stores may have better quality produce, reduce their waste, and this may even impact consumers who may benefit from reduced prices.

Updates Regarding This Third Quarter of 2018

Currently, in Guatemala, 3,860 Liters of CR-10® is being retained for unplanned sales taxes, duties and warehouse costs. An erroneous HS code was assigned in Guatemala holding up the shipment and was contested by our partner in Guatemala. This has been a long process of 10 months and now the product is ready for release and sale to Guatemalan growers.

The good news is there is a demand for the product in Guatemala and we are looking forward to raising the funds from various parties to pay for the warehouse, duties, and taxes so we can complete these sales.

BioNovelus has been watching the current food destabilization in Central America and the resultant caravan to the United States. We know that Coffee Rust is part of the issue and while we know there are multiple and complex factors, we simply ache to get our products and services to these people. Our hearts and prayers are with the people of Central America.

With Michael Goodman now on the Board of Directors, we have been working to take advantage of his sales expertise to create sales structure and strategies and fulfill revenue goals in Guatemala as well as assist the growers in future revenue.

Description of the Issuer's Facilities

The Company was selected to become a resident of the award-winning incubator, the Center of Entrepreneurial Innovation (CEI), located in Phoenix, Arizona. The Company entered into a lease agreement for office space in the CEI on June 1, 2016, renewed the lease for two additional years; the lease will expire on May 31, 2020. The minimum monthly lease payments range from \$551 to \$586. Total rent expenses for the years ended December 31, 2017 and December 31, 2016 were \$5,362 and \$3,344 respectively.



7) Officers, Directors, and Control persons

A. Names of Officers, Directors, and Control Persons.

Jean Ekobo, President, CEO, Chairman of the Board

Nathalie Fournier Ekobo, VP of Marketing & Communications, Secretary, Board Member

Michael D. Goodman, Treasurer, Board Member

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None.

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Jean Ekobo: 37,901,077 common stocks (31.94%)

Nathalie Fournier Ekobo: 23,400,000 common stocks (19.72%)

Meroe Capital Group: 10,000,000 common stocks (8.42%)

Jean Ekobo and Nathalie Fournier Ekobo

c/o BioNovelus Inc.

275 N. Gateway Drive

Suite 130

Phoenix, AZ 85034

David Miller

Meroe Capital Group

44 Wall Street, 12th Floor

New York, NY 10005

8) **Third Party Providers**

Legal Counsel

Frederick F. Taylor

5030 E. Sunrise Dr.

Phoenix AZ 85044

Tel: (480)626-0170

Email: Fred.F.Taylor@gmail.com

Accountant or Auditor

Moffitt & Company
11811 North Tatum Blvd. Suite 2600
Phoenix, AZ 85028
Tel: (480)951-1416
Email: info@moffittandcompany.com

Other Advisor:

Stephen Boatwright
Kennedy and Gallagher PA
2575 East Camelback Road
Phoenix, Arizona, 85016
Tel: 602-530-8000
Fax: 602-530-8500
Email: steve.boatwright@gknet.com

9) Issuer Certification

I, Jean Ekobo, certify that:

1. I have reviewed this Annual Report of BioNovelus, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: Tuesday, November 13, 2018

A handwritten signature in black ink that reads "Ekobo". The signature is written over a horizontal line that extends across the width of the signature.

Jean Ekobo
President/CEO, Chairman of the Board